Home » Interviews » Evgen Pharma Plc CEO Dr Stephen Franklin Interview: SFX-01 Trial Approval
Evgen Pharma Plc

Evgen Pharma Plc CEO Dr Stephen Franklin Interview: SFX-01 Trial Approval

Evgen Pharma Plc (LON:EVG) CEO Dr Stephen Franklin talks to DirectorsTalk about the SFX-01 trial approval for a type of stroke called a Subarachnoid Haemorrhage. Stephen explains what this is, and how SFX-01 is expected to help patients, how long the study will last and the steps that follow.

 

Evgen Pharma Plc is a clinical stage drug development company whose lead programmes are in breast cancer and subarachnoid haemorrhage, a type of stroke. It is also carrying out preclinical work in multiple sclerosis and has a clinical interest in prostate cancer. The Company’s core technology is Sulforadex®, a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane. The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin.

Evgen Pharma commenced operations in January 2008 and is based in Liverpool, UK, at the Liverpool Science Park. It joined the AIM market of the London Stock Exchange in October 2015 and trades under the ticker symbol EVG.

You might also find these articles of interest:

Register here to be notified of future articles like this
Get all our broker ratings on Twitter as they are published!